A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Inclusion Criteria: * Histologically proven CD19- and CD20-positive LBCL, including transformation from indolent lymphomas. * Have disease that is refractory to or relapsed \<=12 months after the completion of first-line chemoimmunotherapy • Refractory disease defined as no complete response (CR) to first-line therapy; participants who are intolerant to first-line therapy are excluded * Progressive disease (PD) as best response to first-line therapy * Stable disease (SD) as best response after at least 4 cycles of first-line therapy (e.g., 4 cycles of R-CHOP) * Partial response (PR) as best response after at least 6 cycles, and biopsy-proven residual disease or disease progression ≤ 12 months from completion of therapy • Relapsed disease defined as CR to first-line therapy followed by biopsy- proven disease relapse ≤ 12 months of completing first-line therapy. * Participants must have received first-line therapy including: * Anti-CD20 monoclonal antibody * An anthracycline containing chemotherapy regimen * Age 18 or older * Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. * Participants must be willing and able to comply with protocol-mandated hospitalization upon administration of the first dose of glofitamab. * Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as: * Absolute neutrophil count ≥ 1000/μL * Platelet count either ≥ 75,000/μL or \>50K if documented lymphomatous involvement of bone marrow * Absolute…